Literature DB >> 27469512

Management of Serotonin Syndrome and Neuroleptic Malignant Syndrome.

Linn E Katus1, Steven J Frucht2.   

Abstract

OPINION STATEMENT: Serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS) can present similarly and range in severity from mild to life-threatening. Although they are easily misdiagnosed, each is distinct clinically and pathophysiologically. It is important to distinguish between the two, as therapeutic options differ. An accurate and thorough medication history plus knowledge of the various clinical presentations of both syndromes are the first steps in management. After this, removing the offending agents and aggressive supportive care are crucial. This includes controlling muscle rigidity and hyperthermia, providing cardiovascular support, and alleviating agitation. In severe cases, paralysis, sedation, and intubation are required. Agents to reverse either surplus serotonergic activity or dopamine blockage can be useful. However, the diagnosis must be clear, as use of these agents in the incorrect syndrome can worsen symptoms. In pharmacologically refractory cases of NMS, electroconvulsive therapy should be pursued.

Entities:  

Keywords:  Complications; Management; Neuroleptic malignant syndrome; Serotonin syndrome; Supportive care; Treatment

Year:  2016        PMID: 27469512     DOI: 10.1007/s11940-016-0423-4

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  13 in total

Review 1.  The serotonin syndrome.

Authors:  H Sternbach
Journal:  Am J Psychiatry       Date:  1991-06       Impact factor: 18.112

Review 2.  The serotonin syndrome.

Authors:  Edward W Boyer; Michael Shannon
Journal:  N Engl J Med       Date:  2005-03-17       Impact factor: 91.245

Review 3.  Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary.

Authors:  Rupal Dosi; Annirudh Ambaliya; Harshal Joshi; Rushad Patell
Journal:  BMJ Case Rep       Date:  2014-06-23

Review 4.  Diagnosis and treatment of drug-induced hyperthermia.

Authors:  Megan E Musselman; Suprat Saely
Journal:  Am J Health Syst Pharm       Date:  2013-01-01       Impact factor: 2.637

Review 5.  Treatment of four psychiatric emergencies in the intensive care unit.

Authors:  O Joseph Bienvenu; Karin J Neufeld; Dale M Needham
Journal:  Crit Care Med       Date:  2012-09       Impact factor: 7.598

Review 6.  Treatment of movement disorder emergencies.

Authors:  Steven J Frucht
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 7.  Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response.

Authors:  Federica Luchini; Pierpaolo Medda; Michela Giorgi Mariani; Mauro Mauri; Cristina Toni; Giulio Perugi
Journal:  World J Psychiatry       Date:  2015-06-22

Review 8.  The parkinsonism-hyperpyrexia syndrome.

Authors:  Edward J Newman; Donald G Grosset; Peter G E Kennedy
Journal:  Neurocrit Care       Date:  2008-08-20       Impact factor: 3.210

9.  Transient serotonin toxicity evoked by combination of electroconvulsive therapy and fluoxetine.

Authors:  René Klysner; Birgitte Bjerg Bendsen; Maja Soon Hansen
Journal:  Case Rep Psychiatry       Date:  2014-06-01

Review 10.  Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report.

Authors:  Julie Langan; Daniel Martin; Polash Shajahan; Daniel J Smith
Journal:  BMC Psychiatry       Date:  2012-11-29       Impact factor: 3.630

View more
  3 in total

Review 1.  The Top 5 Neurotransmitters from a Clinical Neurologist's Perspective.

Authors:  Daniel Kondziella
Journal:  Neurochem Res       Date:  2016-11-08       Impact factor: 3.996

Review 2.  Drug Interactions in Neurocritical Care.

Authors:  Brian Spoelhof; Salia Farrokh; Lucia Rivera-Lara
Journal:  Neurocrit Care       Date:  2017-10       Impact factor: 3.210

Review 3.  Clinical Assessment and Management of Delirium in the Palliative Care Setting.

Authors:  Shirley Harvey Bush; Sallyanne Tierney; Peter Gerard Lawlor
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.